Meeting Banner
Abstract #3760

Fumarate Metabolic Signature for Detecting Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome-associated Renal Cell Carcinoma

Guiqin Liu1, Guangyu Wu1, Yongming Dai2, and Ke Xue2
1Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, 2United Imaing Healthcare, Shanghai, China

Synopsis

Non-invasive in vivo detection of abnormal fumarate accumulation is important for identify fumarate hydratase (FH) deficiency in hereditary leiomyomatosis and renal cell carcinoma (HLRCC). However, until now, no study has been reported to successfully identify fumarate accumulation in HLRCC-associated RCC. In our study, we achieved an 100% accuracy in primary HLRCC-associated RCC, as well as all of the HLRCC PDX models. For our best knowledge, it is the first time that, MRS can be successfully used to in vivo detected in FH-deficient renal lesions, which is a crucial innovation of conventional imaging diagnostic technology.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.

Keywords